Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fobrepodacin - Spero Therapeutics

Drug Profile

Fobrepodacin - Spero Therapeutics

Alternative Names: pVXc-486; SPR-720; VXc-100/VXc486; VXC-486 phosphate

Latest Information Update: 18 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer Spero Therapeutics
  • Class Antibacterials; Antituberculars; Benzimidazoles; Fluorinated hydrocarbons; Furans; Phosphates; Pyrimidines; Urea compounds
  • Mechanism of Action DNA gyrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Nontuberculous mycobacterium infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Nontuberculous mycobacterium infections
  • No development reported Tuberculosis

Most Recent Events

  • 23 Feb 2024 Spero Therapeutics completes a phase I pharmacokinetics trial (In volunteers) in USA (PO, Capsule) (NCT05955586)
  • 18 Oct 2023 Spero Therapeutics completed a pharmacokinetics phase I trial (In volunteers) (PO) (NCT05966688)
  • 01 Aug 2023 Spero Therapeutics initiates a phase I pharmacokinetics trial (In volunteers) in USA (PO, Capsule) (NCT05955586)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top